CME
Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment
September 30, 2020
Host: Robert Mocharnuk, MD
Guest: Hossein Borghaei, MS, DO
The discovery of predictive biomarkers has led to an improvement in overall survival (OS) and progression-free survival (PFS) in non–small cell lung cancer (NSCLC) by identifying subgroups
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!